Cencora, Inc. (COR)
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?
Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised
COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.
Cencora (COR) Beats Q2 Earnings and Revenue Estimates
Cencora (COR) came out with quarterly earnings of $4.42 per share, beating the Zacks Consensus Estimate of $4.08 per share. This compares to earnings of $3.80 per share a year ago.
MedTech Stocks' Earnings to Watch on May 7: COR, QDEL & INGN
The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and personalized care. However, earnings gains were more modest as global tariffs, inflationary costs, and supply chain disruptions continued to pressure margins.
Unveiling Cencora (COR) Q2 Outlook: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Cencora (COR) Earnings Expected to Grow: Should You Buy?
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?
Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes
Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.
Why Cencora (COR) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Add Cencora Stock to Your Portfolio Now
COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
